[go: up one dir, main page]

NO20033548D0 - Modifiserte proteiner, designer toksiner og fremgangsmåter for fremstillingav disse - Google Patents

Modifiserte proteiner, designer toksiner og fremgangsmåter for fremstillingav disse

Info

Publication number
NO20033548D0
NO20033548D0 NO20033548A NO20033548A NO20033548D0 NO 20033548 D0 NO20033548 D0 NO 20033548D0 NO 20033548 A NO20033548 A NO 20033548A NO 20033548 A NO20033548 A NO 20033548A NO 20033548 D0 NO20033548 D0 NO 20033548D0
Authority
NO
Norway
Prior art keywords
preparation
methods
modified proteins
designer toxins
toxins
Prior art date
Application number
NO20033548A
Other languages
English (en)
Other versions
NO20033548L (no
Inventor
Michael G Rosenblum
Lawrence Cheung
Original Assignee
Res Dev Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Dev Foundation filed Critical Res Dev Foundation
Publication of NO20033548D0 publication Critical patent/NO20033548D0/no
Publication of NO20033548L publication Critical patent/NO20033548L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Botany (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
NO20033548A 2001-02-12 2003-08-11 Modifiserte proteiner, designer toksiner og fremgangsmåter for fremstillingav disse NO20033548L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26840201P 2001-02-12 2001-02-12
PCT/US2002/004195 WO2002069886A2 (en) 2001-02-12 2002-02-12 Modified proteins, designer toxins, and methods of making thereof

Publications (2)

Publication Number Publication Date
NO20033548D0 true NO20033548D0 (no) 2003-08-11
NO20033548L NO20033548L (no) 2003-10-10

Family

ID=23022845

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20033548A NO20033548L (no) 2001-02-12 2003-08-11 Modifiserte proteiner, designer toksiner og fremgangsmåter for fremstillingav disse

Country Status (13)

Country Link
US (5) US7083957B2 (no)
EP (1) EP1406644A4 (no)
JP (1) JP2005514000A (no)
KR (2) KR20040022208A (no)
CN (1) CN100413885C (no)
AU (1) AU2002306477B2 (no)
CA (1) CA2438143C (no)
IL (1) IL157228A0 (no)
NO (1) NO20033548L (no)
NZ (1) NZ527501A (no)
RU (2) RU2432358C2 (no)
WO (1) WO2002069886A2 (no)
ZA (1) ZA200305980B (no)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6750329B1 (en) * 1989-05-05 2004-06-15 Research Development Foundation Antibody delivery system for biological response modifiers
IL97776A (en) * 1990-04-19 2000-10-31 Res Dev Foundation Composition comprising a conjugate of a ZME antibody and a biological response modifier
US8110218B2 (en) * 2000-11-30 2012-02-07 The Research Foundation Of State University Of New York Compositions and methods for less immunogenic protein-lipid complexes
ZA200305980B (en) * 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
WO2003007889A2 (en) * 2001-07-17 2003-01-30 Research Development Foundation Therapeutic agents comprising pro-apoptotic proteins
EP1478992A4 (en) * 2002-02-07 2007-03-21 Univ Utah Res Found METHOD FOR PRODUCING AND USING A TREATMENT PROTOCOL
AU2003275985A1 (en) * 2002-06-12 2003-12-31 Research Development Foundation Immunotoxin as a therapeutic agent and uses thereof
US7351688B2 (en) * 2003-02-05 2008-04-01 The Research Foundation Of State University Of New York Compositions and methods for less immunogenic protein formulations
WO2004071420A2 (en) * 2003-02-05 2004-08-26 The Research Foundation Of State University Of New York Compositions and methods for less immunogenic protein formulations
US20050069578A1 (en) * 2003-08-05 2005-03-31 Balasubramanian Sathyamangalam V. Reconstitution medium for protein and peptide formulations
EP1678199B1 (en) * 2003-10-03 2013-03-20 The Board Of Regents, The University Of Texas System Methods and compositions for mycoplasma pneumoniae exotoxins
US8586046B2 (en) 2003-10-03 2013-11-19 Board Of Regents, The University Of Texas System Methods and compositions for mycoplasma pneumoniae exotoxins
EP2457577A1 (en) 2003-11-25 2012-05-30 Anjin Corporation Diphtheria toxin variant
WO2006074451A2 (en) * 2005-01-10 2006-07-13 Research Development Foundation Targeted chimeric molecules for cancer therapy
WO2006083961A2 (en) * 2005-02-01 2006-08-10 Research Development Foundation Blys fusion proteins for targeting blys receptor and methods for treatment of b-cell proliferative disorders
WO2006110132A1 (en) * 2005-04-07 2006-10-19 Board Of Regents, University Of Texas System Methods and compositions for mycoplasma pneumoniae exotoxins
US20090104185A1 (en) * 2005-04-07 2009-04-23 Joel Barry Baseman Methods and Compositions for Mycoplasma Toxins
WO2007002886A2 (en) * 2005-06-29 2007-01-04 The Research Foundation Of State University Of New York Compositions and methods for less immunogenic pr0tein-lip1d complexes
CN100443503C (zh) * 2005-07-18 2008-12-17 四川大学华西医院 人源化ctla-4单链抗体与人穿孔素通道形成肽p34的重组免疫毒素
PL3006458T3 (pl) * 2005-07-29 2018-05-30 The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Services Zmutowane egzotoksyny Pseudomonas o zmniejszonej antygenowości
US7662405B2 (en) * 2005-08-09 2010-02-16 The Research Foundation Of State University Of New York Compositions and methods of preparation of liposomal microparticulate IL-12
WO2007101202A1 (en) * 2006-02-27 2007-09-07 Research Development Foundation Cell-targeted ikb and methods for the use thereof
US7875288B2 (en) * 2006-03-30 2011-01-25 The Research Foundation Of State University Of New York Method for treating blood coagulation disorders
CA2660310C (en) * 2006-03-30 2015-04-21 The Research Foundation Of State University Of New York Compositions of less immunogenic and long-circulating protein-lipid complexes
ATE547123T1 (de) * 2006-04-21 2012-03-15 Mab Factory Gmbh Antikörper-rnase-konjugat
EP2167528B1 (en) * 2007-06-21 2018-01-10 Angelica Therapeutics, INC. Modified toxins
US8470314B2 (en) * 2008-02-29 2013-06-25 Angelica Therapeutics, Inc. Modified toxins
US20100068151A1 (en) * 2008-03-11 2010-03-18 Rosenblum Michael G Multimodality molecular imaging with therapeutic conjugates
CN101671397B (zh) * 2008-10-09 2012-09-05 四川大学 抗EGFR单链抗体融合Gelonin重组免疫毒素及其制备方法与用途
KR101821343B1 (ko) 2010-03-01 2018-01-23 타우 쎄라퓨틱스 엘엘씨 암 진단 및 영상화
SG11201400526TA (en) * 2011-09-12 2014-04-28 Tau Therapeutics Llc Antagonists of products of the hs.459642 unigene cluster for the inhibition of proliferation, development or differentiation of stem cells including cancer stem cells
PL397167A1 (pl) 2011-11-28 2013-06-10 Adamed Spólka Z Ograniczona Odpowiedzialnoscia Przeciwnowotworowe bialko fuzyjne
WO2014055836A2 (en) 2012-10-04 2014-04-10 Research Development Foundation Serine protease molecules and therapies
US9388397B2 (en) * 2013-02-15 2016-07-12 Research Development Foundation Deimmunized gelonin molecules and therapies
CA2902905A1 (en) 2013-03-15 2014-09-25 Claude Geoffrey Davis Modified toxins
US11020486B2 (en) 2013-11-05 2021-06-01 3M Innovative Properties Company Sesame oil based injection formulations
EP2871190A1 (en) * 2013-11-11 2015-05-13 ATLAB Pharma Antibody against GD2-O-acetylated ganglioside with pro-apoptotic activity
CA2986388C (en) * 2015-06-11 2024-02-27 Genexine, Inc. Modified interleukin-7 protein and uses thereof
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
EP3813863A4 (en) * 2018-06-28 2022-07-06 Dana Farber Cancer Institute, Inc. TARGETING OF MULTIPLE ANTIGENS WITH MULTIPLEX CAR-T CELLS IN SOLID AND LIQUID MALIGNOS
US11345967B2 (en) 2019-05-23 2022-05-31 Paradigm Diagnostics Tissue preparation using nuclease

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4263279A (en) 1975-08-19 1981-04-21 Yeda Research & Development Co. Ltd Pharmaceutically active compositions containing adriamycin and daunomycin
GB1564666A (en) 1978-05-31 1980-04-10 Ng Mun Hon Heterocomplexes of interferon with immunoglobulin and pharmaceutical compositions thereof
JPS5686121A (en) 1979-12-14 1981-07-13 Teijin Ltd Antitumor proten complex and its preparation
FR2504010B1 (fr) 1981-04-15 1985-10-25 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
US4522918A (en) 1981-12-15 1985-06-11 Jeffery Schlom Process for producing monoclonal antibodies reactive with human breast cancer
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
EP0118365B1 (en) 1983-03-04 1990-08-29 Health Research, Inc. Monoclonal antibodies to human breast carcinoma cells and their use in diagnosis and therapy
FR2546756B1 (fr) 1983-06-03 1985-11-29 Centre Nat Rech Scient Nouveaux derives immunostimulants, leur preparation et leur application comme medicament
GB2148299B (en) 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
US4666845A (en) * 1983-12-16 1987-05-19 Sloan-Kettering Institute Monoclonal antibodies to ovarian, cervical and uterine human cancers and method of diagnosis
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
US4894443A (en) 1984-02-08 1990-01-16 Cetus Corporation Toxin conjugates
US4753894A (en) 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
EP0160446B1 (en) 1984-05-01 1992-06-17 Ciba Corning Diagnostics Corp. Breast tumor-associated antigen and monoclonal antibodies specific thereto
FR2566271B1 (fr) 1984-06-20 1986-11-07 Sanofi Sa Nouveaux conjugues cytotoxiques utilisables en therapeutique et procede d'obtention
US4650674A (en) 1984-07-05 1987-03-17 Genentech, Inc. Synergistic cytotoxic composition
US4590071A (en) 1984-09-25 1986-05-20 Xoma Corporation Human melanoma specific immunotoxins
US4677064A (en) 1984-11-09 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4708930A (en) 1984-11-09 1987-11-24 Coulter Corporation Monoclonal antibody to a human carcinoma tumor associated antigen
US5032521A (en) 1984-12-05 1991-07-16 The Salk Institute For Biological Studies Monoclonal antibody specific for a mammary tumor cell surface antigen
DE3585778D1 (de) 1984-12-05 1992-05-07 Salk Inst For Biological Studi Monoklonaler antikoerper, spezifisch fuer brustkrebszelloberflaechenantigen.
CA1339798C (en) 1985-02-01 1998-04-07 Alan N. Houghton Method for treatment of neuroectodermal malignancies and epithelial carcinomas in humans
WO1986005098A1 (en) 1985-03-04 1986-09-12 Dana-Farber Cancer Institute, Inc. Immunotoxin and method of making
US4888415A (en) 1985-03-04 1989-12-19 Dana-Farber Cancer Institute, Inc. Gelonin immunotoxin
US6084073A (en) 1985-03-25 2000-07-04 Chiron Corporation Recombinant ricin toxin
DE3676670D1 (de) 1985-06-26 1991-02-07 Cetus Corp Solubilisierung von proteinen fuer pharmazeutische zusammensetzungen mittels polymerkonjugierung.
US4870163A (en) 1985-08-29 1989-09-26 New York Blood Center, Inc. Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor
EP0222360A3 (en) 1985-11-12 1989-03-15 Biotherapeutics Inc. A method of producing a patient-specific cytotoxic reagent and composition
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4962188A (en) 1985-12-06 1990-10-09 Cetus Corporation Recombinant ricin toxin A chain conjugates
DE3685485D1 (de) 1985-12-06 1992-07-02 Cetus Corp Anti-immuntoxine gegen menschlichen eierstockkrebs und verfahren zu deren verwendung.
US4831122A (en) 1986-01-09 1989-05-16 Regents Of The University Of Minnesota Radioimmunotoxins
JPS62190200A (ja) 1986-02-17 1987-08-20 Res Dev Corp Of Japan 抗腫瘍蛋白複合体およびその製造方法
US4894227A (en) 1986-08-01 1990-01-16 Cetus Corporation Composition of immunotoxins with interleukin-2
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4771128A (en) 1986-10-10 1988-09-13 Cetus Corporation Method of purifying toxin conjugates using hydrophobic interaction chromatography
US5019368A (en) 1989-02-23 1991-05-28 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
US4861581A (en) 1986-12-05 1989-08-29 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
US4963354A (en) 1987-01-21 1990-10-16 Genentech, Inc. Use of tumor necrosis factor (TNF) as an adjuvant
JPS63190200A (ja) 1987-02-03 1988-08-05 Toyota Motor Corp 電着塗装後処理方法
US4894225A (en) 1987-03-02 1990-01-16 Cetus Corporation Combination therapy using antitumor immunotoxins with tumor necrosis factor
EP0282057A3 (en) 1987-03-11 1990-03-07 The Board Of Regents Of The University Of Michigan Chemo-radio-immuno-conjugates
US4971792A (en) * 1987-03-27 1990-11-20 The Wistar Institute Monoclonal antibodies against glycolipid antigens
AU612370B2 (en) 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
US4863726A (en) 1987-05-29 1989-09-05 Cetus Corporation Combination therapy using immunotoxins with interleukin-2
WO1988009343A1 (en) 1987-05-29 1988-12-01 Sagami Chemical Research Center Fused protein containing lymphotoxin
CA1341235C (en) 1987-07-24 2001-05-22 Randy R. Robinson Modular assembly of antibody genes, antibodies prepared thereby and use
PH26813A (en) 1987-09-02 1992-11-05 Ciba Geigy Ag Conjugates of cytokines with immunoglobulins
US5017371A (en) 1988-01-06 1991-05-21 Amarillo Cell Culture Company, Incorporated Method for reducing side effects of cancer therapy
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US4867962A (en) 1988-02-26 1989-09-19 Neorx Corporation Functionally specific antibodies
CA1329119C (en) 1988-03-29 1994-05-03 Milton David Goldenberg Cytotoxic therapy
IE62463B1 (en) 1988-07-07 1995-02-08 Res Dev Foundation Immunoconjugates for cancer diagnosis and therapy
US5135736A (en) * 1988-08-15 1992-08-04 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
US5134075A (en) 1989-02-17 1992-07-28 Oncogen Limited Partnership Monoclonal antibody to novel antigen associated with human tumors
US6750329B1 (en) 1989-05-05 2004-06-15 Research Development Foundation Antibody delivery system for biological response modifiers
ZA902949B (en) 1989-05-05 1992-02-26 Res Dev Foundation A novel antibody delivery system for biological response modifiers
IL97776A (en) * 1990-04-19 2000-10-31 Res Dev Foundation Composition comprising a conjugate of a ZME antibody and a biological response modifier
US6306626B1 (en) 1990-04-27 2001-10-23 Research Development Foundation Anti-IgM monoclonal antibodies and methods of their use
IE912716A1 (en) 1990-08-14 1992-02-26 Res Dev Foundation Protein Structure of the Plant Toxin Gelonin
US6099842A (en) 1990-12-03 2000-08-08 The United States Of America As Represented By The Department Of Health And Human Services Recombinant immunotoxin composed of a single chain antibody reacting with the human transferrin receptor and diptheria toxin
EP0561907B1 (en) * 1990-12-05 1998-09-02 Novo Nordisk A/S Proteins with changed epitopes and methods for the production thereof
EP0517895B1 (en) 1990-12-14 1996-11-20 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
ATE173023T1 (de) 1991-09-06 1998-11-15 Res Dev Foundation Dna-sequenzen kodierend für das polypeptid gelonin
US5837491A (en) 1991-11-04 1998-11-17 Xoma Corporation Polynucleotides encoding gelonin sequences
WO1994026910A1 (en) 1993-05-12 1994-11-24 Xoma Corporation Immunotoxins comprising gelonin and an antibody
US5621083A (en) 1991-11-04 1997-04-15 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
US6599505B1 (en) 1992-04-10 2003-07-29 Research Development Foundation Immunotoxins directed against CD33 related surface antigens
US5851829A (en) 1993-07-16 1998-12-22 Dana-Farber Cancer Institute Method of intracellular binding of target molecules
IL112372A (en) 1994-02-07 2001-08-26 Res Dev Foundation Non-viral vector for the delivery of genetic information to cells
US5942230A (en) * 1994-05-06 1999-08-24 The United States Of America As Represented By The Department Of Health And Human Services Composition of immunotoxins and retinoids and use thereof
GB9506466D0 (en) * 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
IL116559A (en) 1995-11-17 2005-11-20 Yissum Res Dev Co Chimeric protein consisting of a bacterial toxin and a myelin basic protein sequence
IL116436A (en) 1995-12-18 2006-12-31 Yissum Res Dev Co Fc?Á-PE CHIMERIC PROTEIN FOR TARGETED TREATMENT OF ALLERGY RESPONSES AND
US5851815A (en) * 1996-03-19 1998-12-22 Idun Pharmaceuticals, Inc. MCH4 and MCH5, apoptotic proteases
IL118570A (en) 1996-06-04 2007-06-17 Shai Yarkoni Use of a chimeric protein that includes Met – GnRH in the preparation of a pharmaceutical preparation for the treatment of adenocarcinoma or patocarcinoma
CN1286530C (zh) 1997-02-28 2006-11-29 贝林格尔·英格海姆药物公司 通过基因治疗炎性细胞的自我调节的细胞凋亡
EP0893493A3 (de) 1997-07-21 2002-12-04 Aventis Pharma Deutschland GmbH Genetisch veränderte Zellen und deren Verwendung in der Prophylaxe oder Therapie von Erkrankungen
AU2521999A (en) 1998-02-04 1999-08-23 Desire Jose Collen Identification, production and use of staphylokinase derivatives with reduced immunogenicity and/or reduced clearance
JP2002504381A (ja) 1998-02-27 2002-02-12 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 遺伝子治療による炎症性細胞の自己調節アポトーシス
US6645490B2 (en) 1998-03-02 2003-11-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Chimeric proteins with cell-targeting specificity and apoptosis-inducing activities
US6140066A (en) 1998-03-24 2000-10-31 Lorberboum-Galski; Haya Methods of cancer diagnosis using a chimeric toxin
EP1066404A4 (en) 1998-04-03 2004-04-07 Invitrogen Corp METHOD FOR PRODUCING LIBRARIES OF EXPRESSABLE GENE SEQUENCES
EP1066309A4 (en) 1998-04-03 2005-10-19 Invitrogen Corp LIBRARIES OF EXPRESSIBLE GENESQUENCES
US20040009477A1 (en) 1998-04-03 2004-01-15 Invitrogen Corporation Methods for producing libraries of expressible gene sequences
US6835550B1 (en) * 1998-04-15 2004-12-28 Genencor International, Inc. Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
CU22732A1 (es) * 1998-08-14 2002-02-28 Ct Ingenieria Genetica Biotech Mutantes de estreptoquinasa
WO2000026406A1 (en) 1998-11-04 2000-05-11 Digital Gene Technologies, Inc. METHOD FOR INDEXING AND DETERMINING THE RELATIVE CONCENTRATION OF EXPRESSED MESSENGER RNAs
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
DE19900743A1 (de) 1999-01-12 2000-07-13 Aventis Pharma Gmbh Neue komplexbildende Proteine
US6703020B1 (en) * 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
US6639054B1 (en) * 2000-01-06 2003-10-28 Monsanto Technology Llc Preparation of deallergenized proteins and permuteins
DE50112965D1 (de) 2000-04-22 2007-10-18 Pharmedartis Gmbh Apoptotika
WO2002042420A2 (en) 2000-11-21 2002-05-30 Digital Gene Technologies, Inc. Modulation of gene expression during intimal hyperplasia of the carotid artery
ZA200305980B (en) * 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
AU2002306768A1 (en) 2001-03-20 2002-10-03 Ortho-Clinical Diagnostics, Inc. Expression profiles and methods of use
GB0116047D0 (en) 2001-06-29 2001-08-22 Implyx Ltd Peptide motif for therapy
WO2003007889A2 (en) 2001-07-17 2003-01-30 Research Development Foundation Therapeutic agents comprising pro-apoptotic proteins
AU2003275985A1 (en) 2002-06-12 2003-12-31 Research Development Foundation Immunotoxin as a therapeutic agent and uses thereof

Also Published As

Publication number Publication date
RU2003127678A (ru) 2005-01-20
EP1406644A4 (en) 2005-03-16
KR20040022208A (ko) 2004-03-11
US7285635B2 (en) 2007-10-23
US20030176331A1 (en) 2003-09-18
RU2305684C2 (ru) 2007-09-10
US20100247518A1 (en) 2010-09-30
ZA200305980B (en) 2007-01-31
EP1406644A2 (en) 2004-04-14
CN1512888A (zh) 2004-07-14
US7741278B2 (en) 2010-06-22
US8138311B2 (en) 2012-03-20
US20110288275A1 (en) 2011-11-24
CA2438143A1 (en) 2002-09-12
AU2002306477B2 (en) 2008-07-10
US7943571B2 (en) 2011-05-17
KR20080056315A (ko) 2008-06-20
WO2002069886A2 (en) 2002-09-12
CA2438143C (en) 2010-01-12
CN100413885C (zh) 2008-08-27
NO20033548L (no) 2003-10-10
JP2005514000A (ja) 2005-05-19
US7083957B2 (en) 2006-08-01
RU2007112876A (ru) 2008-10-20
RU2432358C2 (ru) 2011-10-27
IL157228A0 (en) 2004-02-19
WO2002069886A3 (en) 2004-01-22
US20070036780A1 (en) 2007-02-15
NZ527501A (en) 2006-04-28
US20080292544A1 (en) 2008-11-27

Similar Documents

Publication Publication Date Title
NO20033548D0 (no) Modifiserte proteiner, designer toksiner og fremgangsmåter for fremstillingav disse
DK1309692T3 (da) Anti-IL12-antistoffer, præparater, fremgangsmåder og anvendelser
CY2019029I1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοi και χρησεις
DK1390389T3 (da) Cripto-blokerende antistoffer og anvendelser deraf
NO20033387L (no) Modifiserte antistoffer og fremgangsmåter for anvendelse
NO20034962D0 (no) Beta-amyloid peptid-bindende proteiner og polynukleotider som koder for samme
IS6881A (is) Samsett fjölgilt fjölsykru-próteinbóluefni gegn heilasóttarhnettlu
IL228034A0 (en) Formulations with a high concentration of antibodies and proteins
AU2002351239A8 (en) Antibody to latent membrane proteins and uses thereof
EP1490094A4 (en) ANTIBODY FUSION PROTEINS AS EFFECTIVE ADJUVANTS FOR PROTEIN VACCINATION
NO20033418L (no) Immunregulatoriske antistoffer og anvendelse derav
NO20034405D0 (no) Anti-ostepontin-antistoff og anvendelse derav
DK1511734T3 (da) Forbindelser, præparater og fremgangsmåder
DE60226425D1 (de) Lösliches rage-protein
EE200300569A (et) CD44v6-spetsiifilised antikehad
DE60212776D1 (de) Spezifisches Bindungsanalyseverfahren
AU2002365269A8 (en) Mut-il-18 or mut-il-18r proteins, antibodies, compositions, methods and uses
NO20024105L (no) Memnopeptider, fremgangsmåte for deres fremstilling og anvendelse av disse
EP1578906A4 (en) AFAP SEQUENCES, POLYPEPTIDES, ANTIBODIES AND METHODS
EP1252190A4 (en) PROTEIN-SPECIFIC ANTIBODIES HAVING POLYGLUTAMINE EXPANSIONS
AU2002257052A8 (en) Reg-like protein immunoglobulin derived proteins, compositions, methods and uses
EP1444250A4 (en) GROEL CHIMERIC PROTEIN AND VACCINE
SE0001979D0 (sv) Protein and method using said protein
EP1461064A4 (en) BOVINE LEPTINE PROTEIN, ANTISENSE AND ANTIBODIES
ATE480262T1 (de) Fusionsproteine

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application